Bitzén P O, Melander A, Scherstén B, Wåhlin-Boll E
Department of Community Health Sciences, Lund University Health Sciences Centre, Dalby, Sweden.
Eur J Clin Pharmacol. 1988;35(1):31-7. doi: 10.1007/BF00555504.
An early defect in subjects with non-insulin-dependent diabetes mellitus (NIDDM) and the preceding phase of impaired glucose tolerance (IGT) is a reduction in early insulin release and hence a prolonged elevation of postprandial blood glucose. We therefore assessed whether a rapidly acting sulphonylurea (glipizide 5 mg 0.5 h before a test meal) could correct these disturbances in 38 IGT/NIDDM subjects, whose early insulin release and postprandial blood glucose elevations remained unimproved after 10 weeks of dietary regulation. We also assessed whether the efficacy of glipizide was dependent upon the ambient blood glucose concentration, and if early systemic availability of the drug was important for the blood glucose lowering effect. A single dose of glipizide normalized early insulin release and hence reduced the postprandial blood glucose increase that was not lowered by dietary regulation. The efficacy of glipizide was dependent upon the early systemic availability of the drug, but early systemic availability and efficacy were independent of the extent of blood glucose elevation, at least within a range of 6-12 mmol.l-1 of fasting blood glucose.
非胰岛素依赖型糖尿病(NIDDM)患者以及处于糖耐量受损(IGT)前期阶段的患者,早期存在的一个缺陷是早期胰岛素释放减少,进而导致餐后血糖长时间升高。因此,我们评估了一种速效磺脲类药物(在试验餐前进食0.5小时服用5毫克格列吡嗪)能否纠正38例IGT/NIDDM患者的这些紊乱情况。这些患者在经过10周的饮食调节后,其早期胰岛素释放和餐后血糖升高情况仍未得到改善。我们还评估了格列吡嗪的疗效是否取决于周围血糖浓度,以及药物的早期全身可用性对血糖降低效果是否重要。单剂量格列吡嗪可使早期胰岛素释放正常化,从而减少了饮食调节未能降低的餐后血糖升高。格列吡嗪的疗效取决于药物的早期全身可用性,但早期全身可用性和疗效与血糖升高程度无关,至少在空腹血糖6 - 12毫摩尔/升的范围内是如此。